A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

Official title

A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age

Study identification

NCT ID

NCT02914275

Recruitment status

Completed

Study type

Interventional

Phase

Phase 3

Lead sponsor

Seqirus

Industry

Enrollment

2,250 participants

Conditions and interventions

Eligibility (public fields only)

Age range

6 Months to 59 Months

Sex

All

Healthy volunteers

Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Sep 27, 2016 (Actual)

Primary completion

Mar 9, 2017 (Actual)

Completion

Aug 11, 2017 (Actual)

Last update posted

Jan 23, 2019

2016 – 2017

United States locations

U.S. sites

39

U.S. states

15

U.S. cities

30

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.